Process
Pawvlov was evaluated and built by the NLT Labs automated pipeline — specialized agents evaluated the market (PE score 7.1/10, FUND verdict), analyzed the competitive landscape (therapy use case uncontested), designed the product (hardware BOM modeled at $26.05 @10K), wrote the copy, and the builder composed this site — in a single pipeline run.
Why funded
Furbo and Petcube both pivoted to remote-engagement features in 2025, leaving the therapy use case entirely open. Entry timing matters when the competitive gap just opened. The pipeline flagged this as the primary reason to fund.
Why funded
Systematic desensitization + counter-conditioning is peer-reviewed, clinically validated by the DACVB community, and requires a 3-member scientific advisory board to claim credibly. Copying the product is easier than copying the clinical positioning. The 3-DACVB SAB is a structural moat.
Why funded
82.9% hardware gross margin at 10K units on $219 retail (market-anchored). ESP32-S3 plus on-device INT8 inference at sub-$4 BOM is a 2024-25 cost inflection — this product was not economically viable 2 years ago. BOM modeled from component-level pricing (Digi-Key, Mouser, LCSC).
Top risk
If the device dispenses during a fear state, one documented viral failure thread on r/dogs collapses the brand positioning. Mitigation: 95% calm-state precision target, confidence threshold 0.7, SAB-supervised concierge MVP, hardcoded never-dispense-during-fear override. Severity: critical; likelihood: low. (modeled)
Top risk
$105K CapEx for 3 chassis sizes, 8-12 week Shenzhen lead time, dominant critical path risk. Delay pushes launch from Month 18 to Month 24+. Mitigation: lock partner + lead-time commitment in writing by Phase 2 Month 2; stage 30% deposit on Phase 3 go-signal. (sourced)
PE score 7.1/10, FUND verdict. Run ID: 0a113dbcec3749bab34e79ad7124efcd. Evaluated 2026-06-18. Top-quartile hardware concept in NLT Labs 2025-2026 PE pipeline.
Market opportunity
36M noise-anxious dogs · $630M SAM · 8-12% CAGR · sourced
Competitive dynamics
Therapy use case uncontested · Furbo iatrogenic · DACVB supply-scarce · sourced
Technical feasibility
ESP32-S3 INT8 inference proven · 92% classifier target · cloud fallback path · modeled
Financial model quality
82.9% GM @10K · LTV:CAC 10.9:1 · $50K MRR Month 18 · modeled
Regulatory posture
Consumer training aid · no FDA path · FCC Part 15B+15C in budget · sourced
Pipeline Run Telemetry
20 agents · same phases as
portfolio.nltlabs.ai/pipeline.
Cards show live stats from pipeline-run.json.
Partial pipeline telemetry
Lineage: PE evaluation + POC build.
Flags: workflow_in_progress
Quality scorecard
Iatrogenic harm risk is structural, not solved: the device's value prop attacks Furbo for rewarding during fear states, but Pawvlov's own ESP32-S3 4-class classifier running at 5fps on novel pose data (no public labeled dataset exists per feas brief) will inevitably misclassify and reward fear states. One viral 'Pawvlov made my dog worse' Reddit thread destroys the entire 'therapy, not toy' positioning the brand is built on — this is a brand-existential risk the founder explicitly created by accusing competitors of the same failure mode.
$215K seed is critically underfunded with zero CAC budget: $105K tooling + $45K eng + $12K SAB + $12K FCC + $9K beta + $6K insurance + $4K reserve = $193K committed before any marketing, customer acquisition, founder salary beyond 90 days, working capital for inventory restock, classifier data collection (10K+ labeled frames), or contingency. The fin brief assumes 3.5K Y1 units sold with no documented CAC channel and no marketing line item. Hardware DTC with $0 acquisition budget does not ship 3.5K units.
Timeline math is broken: 90-day MVP is contradicted by the feas brief (6-9 month industry norm), 8-12 week tooling, 8-12 week FCC cert, and a non-existent labeled training dataset. Realistic first ship is month 9-12, leaving 0-3 months in Y1 to hit the fin brief's $1M revenue target. Seed funds only ~12 months of opex per fin brief; a 3-month slip burns the entire runway before unit-1 retail.
TAM ~$2.16B by applying ~$60 annual anxiety-solution spend across the ~36M US dogs with noise anxiety → The $60/year/dog multiplier has no cited source. ThunderShirt is a $40 one-time purchase, Adaptil diffusers are $25-60/year, and trazodone runs $15-40/month for severe cases only (~5-10% of anxious dogs, not 33%). The 33% prevalence figure is owner-reported behavioral observation, not clinical diagnosis — addressable population for a $249 device is materially smaller. Realistic TAM is likely $300-500M, not $2.16B.
Moat score of 4 with silent-auger + floor-tray delivery, DACVB SAB endorsement, and 'therapy not toy' brand wedge as defensibility → None of these are durable moats. The silent auger is mechanical engineering, not patentable IP — PETLIBRO/Furbo can replicate in one hardware cycle. SAB endorsements transfer to any well-funded competitor. The 'therapy' brand wedge is an FTC substantiation liability without clinical trials, not a moat. Comp brief admits incumbents could ship anxiety mode in 12-18 months; realistic moat score is 2-3.
Feasibility score 6 with 90-day MVP buildable using mature off-the-shelf components → The feas brief itself contradicts the score by flagging the 90-day timeline as ~2-3x unrealistic, the labeled dataset as non-existent, the auger spec as aggressive, and the 49% tooling commitment as the dominant capital risk. With four structural unknowns (classifier accuracy, dataset acquisition, auger noise floor, 3-SKU coordination), the score should be 3-4, not 6.
Year 1 revenue $1M with breakeven month 18, assuming 70% subscription attach and $60-90 CAC → Both undefended assumptions. Furbo Nanny attach reportedly <30%; Peloton attach <50%. DTC pet-hardware CAC benchmarks $100-200. At 40% attach and $150 CAC, the fin brief's own sensitivities show breakeven slips past month 24 — beyond the seed runway. The Y1 $1M figure also requires 3.5K units shipped, which assumes first retail ship by month 6 — impossible given 8-12 week tooling + 8-12 week FCC + non-existent classifier dataset.
Risk level 'medium' with FCC + UL certifications and ToS architecture sufficient to manage state privacy/biometric exposure → Continuous in-home camera doing pose classification plus always-on audio recording in two-party-consent states is high-risk, not medium. BIPA class actions have settled at $650M (Facebook), $92M (TikTok). Pose data may qualify as biometric identifier under IL/TX/WA statutes. Cloud inference path means data leaves the device, eliminating the 'on-device' defense. Risk level should be elevated to high; a single BIPA class certification kills the company.
Showing first 8 of 9 decisions.
Pipeline v3.2 · run 2026-06-20 · pe=0a113dbc · poc=1fe2d510